サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1487567

ファーマージング（新興医薬品）市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Pharmerging Market (Product Type: Pharmaceuticals and Healthcare; and Indication: Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 192 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
ファーマージング（新興医薬品）市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月16日
発行: Transparency Market Research
ページ情報: 英文 192 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファーマージング（新興医薬品）市場- 調査範囲

TMRの調査レポート「ファーマージング（新興医薬品）の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界のファーマージング（新興医薬品）市場の収益と予測を提供します。また、2024年から2034年までの世界のファーマージング（新興医薬品）市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照しました。

市場スナップショット
2023年の市場規模 21億米ドル
2034年の市場価値 71億米ドル
CAGR 11.6%

本レポートでは、世界のファーマージング（新興医薬品）市場の競合情勢について掘り下げています。世界の製薬市場で事業を展開する主要企業が特定され、その各企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の製薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 市場分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品タイプ/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：製品タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製品タイプ別、2020-2034年
    • 医薬品
      • ブランド処方薬
      • ジェネリック医薬品
        • ブランドジェネリック医薬品
        • ブランドなしジェネリック医薬品
      • OTC医薬品
    • ヘルスケア
      • 医療機器
      • 診断機器
      • その他（IT・記録管理）
  • 市場魅力度分析：製品タイプ別

第7章 世界市場分析・予測：適応症別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：適応症別、2020年～2034年
    • 生活習慣病
    • がんおよび自己免疫疾患
    • 感染症
    • その他
  • 市場魅力度分析：適応症別

第8章 世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2020年～2034年
    • 病院
    • 診療所
    • 小売薬局
    • eコマース
    • ドラッグストア
  • 市場魅力度分析：流通チャネル別

第9章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別, 2020-2034
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東・アフリカ市場の分析と予測

第14章 競合情勢

  • 市場競合マトリックス（企業階層別・企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Abbott Laboratories
    • Koninklijke Philips N.V.
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca
    • GlaxoSmithKline plc
    • Lupin
    • Tata Consultancy Services Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Huadong Medicine Co., Ltd.
図表

List of Tables

  • Table 01: Global Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
  • Table 02: Global Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 03: Global Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Pharmerging Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: Europe Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 06: Europe Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
  • Table 07: Europe Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 08: Europe Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 09: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
  • Table 11: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 12: Asia Pacific Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 13: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
  • Table 15: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 16: Latin America Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 17: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Product Type, 2020-2034
  • Table 19: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Indication, 2020-2034
  • Table 20: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Pharmerging Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Pharmerging Market Revenue (US$ Mn), by Product Type, 2023
  • Figure 03: Global Pharmerging Market Value Share, by Product Type, 2023
  • Figure 04: Global Pharmerging Market Revenue (US$ Mn), by Indication, 2023
  • Figure 05: Global Pharmerging Market Value Share, by Indication, 2023
  • Figure 06: Global Pharmerging Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 07: Global Pharmerging Market Value Share, by Distribution Channel, 2023
  • Figure 08: Global Pharmerging Market Value Share, by Region, 2023
  • Figure 09: Global Pharmerging Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 11: Global Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 13: Global Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 14: Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 15: Global Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 16: Global Pharmerging Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: Europe Pharmerging Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: Europe Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 20: Europe Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 21: Europe Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 22: Europe Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 23: Europe Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 24: Europe Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: Europe Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 26: Europe Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 27: Asia Pacific Pharmerging Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Asia Pacific Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Asia Pacific Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Asia Pacific Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 31: Asia Pacific Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 32: Asia Pacific Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 33: Asia Pacific Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Asia Pacific Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 35: Asia Pacific Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 36: Latin America Pharmerging Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Latin America Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Latin America Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Latin America Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 40: Latin America Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 41: Latin America Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 42: Latin America Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Latin America Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 44: Latin America Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 45: Middle East & Africa Pharmerging Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Middle East & Africa Pharmerging Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Middle East & Africa Pharmerging Market Value Share Analysis, by Product Type, 2023 and 2034
  • Figure 49: Middle East & Africa Pharmerging Market Value Share Analysis, by Indication, 2023 and 2034
  • Figure 50: Middle East & Africa Pharmerging Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Indication, 2024-2034
  • Figure 53: Middle East & Africa Pharmerging Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL8200

Pharmerging Market - Scope of Report

TMR's report on the global pharmerging market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global pharmerging market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharmerging market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmerging market.

Market Snapshot
Market Value in 2023US$ 2.1 Bn
Market Value in 2034US$ 7.1 Bn
CAGR11.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharmerging market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharmerging market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharmerging market.

The report delves into the competitive landscape of the global pharmerging market. Key players operating in the global pharmerging market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharmerging market profiled in this report.

Key Questions Answered in Global pharmerging Market Report:

  • What is the sales/revenue generated by pharmerging across all regions during the forecast period?
  • What are the opportunities in the global pharmerging market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Pharmerging Market - Research Objectives and Research Approach

The comprehensive report on the global pharmerging market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pharmerging market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmerging market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Pharmerging Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Type Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Pharmerging Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product Type /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Pharmerging Market Analysis and Forecast, by Product Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Product Type, 2020-2034
    • 6.3.1. Pharmaceuticals
      • 6.3.1.1. Branded Prescription Drugs
      • 6.3.1.2. Generic Drugs
        • 6.3.1.2.1. Branded Generics
        • 6.3.1.2.2. Unbranded Generics
      • 6.3.1.3. OTC Drugs
    • 6.3.2. Healthcare
      • 6.3.2.1. Medical Devices
      • 6.3.2.2. Diagnostic Instruments
      • 6.3.2.3. Others (IT and Record Management)
  • 6.4. Market Attractiveness Analysis, by Product Type

7. Global Pharmerging Market Analysis and Forecast, by Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Indication, 2020-2034
    • 7.3.1. Lifestyle Diseases
    • 7.3.2. Cancer and Autoimmune Diseases
    • 7.3.3. Infectious Diseases
    • 7.3.4. Others
  • 7.4. Market Attractiveness Analysis, by Indication

8. Global Pharmerging Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Retail Pharmacies
    • 8.3.4. E-commerce
    • 8.3.5. Drugs Stores
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Pharmerging Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. Europe
    • 9.2.2. Asia Pacific
    • 9.2.3. Latin America
    • 9.2.4. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. Europe Pharmerging Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Product Type, 2020-2034
    • 10.3.1. Pharmaceuticals
      • 10.3.1.1. Branded Prescription Drugs
      • 10.3.1.2. Generic Drugs
        • 10.3.1.2.1. Branded Generics
        • 10.3.1.2.2. Unbranded Generics
      • 10.3.1.3. OTC Drugs
    • 10.3.2. Healthcare
      • 10.3.2.1. Medical Devices
      • 10.3.2.2. Diagnostic Instruments
      • 10.3.2.3. Others (IT and Record Management)
  • 10.4. Market Value Forecast, by Indication, 2020-2034
    • 10.4.1. Lifestyle Diseases
    • 10.4.2. Cancer and Autoimmune Diseases
    • 10.4.3. Infectious Diseases
    • 10.4.4. Others
  • 10.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 10.5.1. Hospitals
    • 10.5.2. Clinics
    • 10.5.3. Retail Pharmacies
    • 10.5.4. E-commerce
    • 10.5.5. Drugs Stores
  • 10.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.6.1. Germany
    • 10.6.2. U.K.
    • 10.6.3. France
    • 10.6.4. Italy
    • 10.6.5. Spain
    • 10.6.6. Rest of Europe
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Product Type
    • 10.7.2. By Indication
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country/Sub-region

11. Asia Pacific Pharmerging Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Product Type, 2020-2034
    • 11.3.1. Pharmaceuticals
      • 11.3.1.1. Branded Prescription Drugs
      • 11.3.1.2. Generic Drugs
        • 11.3.1.2.1. Branded Generics
        • 11.3.1.2.2. Unbranded Generics
      • 11.3.1.3. OTC Drugs
    • 11.3.2. Healthcare
      • 11.3.2.1. Medical Devices
      • 11.3.2.2. Diagnostic Instruments
      • 11.3.2.3. Others (IT and Record Management)
  • 11.4. Market Value Forecast, by Indication, 2020-2034
    • 11.4.1. Lifestyle Diseases
    • 11.4.2. Cancer and Autoimmune Diseases
    • 11.4.3. Infectious Diseases
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.5.1. Hospitals
    • 11.5.2. Clinics
    • 11.5.3. Retail Pharmacies
    • 11.5.4. E-commerce
    • 11.5.5. Drugs Stores
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. China
    • 11.6.2. India
    • 11.6.3. Rest of Asia Pacific
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Product Type
    • 11.7.2. By Indication
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Latin America Pharmerging Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Product Type, 2020-2034
    • 12.3.1. Pharmaceuticals
      • 12.3.1.1. Branded Prescription Drugs
      • 12.3.1.2. Generic Drugs
        • 12.3.1.2.1. Branded Generics
        • 12.3.1.2.2. Unbranded Generics
      • 12.3.1.3. OTC Drugs
    • 12.3.2. Healthcare
      • 12.3.2.1. Medical Devices
      • 12.3.2.2. Diagnostic Instruments
      • 12.3.2.3. Others (IT and Record Management)
  • 12.4. Market Value Forecast, by Indication, 2020-2034
    • 12.4.1. Lifestyle Diseases
    • 12.4.2. Cancer and Autoimmune Diseases
    • 12.4.3. Infectious Diseases
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.5.1. Hospitals
    • 12.5.2. Clinics
    • 12.5.3. Retail Pharmacies
    • 12.5.4. E-commerce
    • 12.5.5. Drugs Stores
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. Brazil
    • 12.6.2. Mexico
    • 12.6.3. Rest of Latin America
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Product Type
    • 12.7.2. By Indication
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Middle East & Africa Pharmerging Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Product Type, 2020-2034
    • 13.3.1. Pharmaceuticals
      • 13.3.1.1. Branded Prescription Drugs
      • 13.3.1.2. Generic Drugs
        • 13.3.1.2.1. Branded Generics
        • 13.3.1.2.2. Unbranded Generics
      • 13.3.1.3. OTC Drugs
    • 13.3.2. Healthcare
      • 13.3.2.1. Medical Devices
      • 13.3.2.2. Diagnostic Instruments
      • 13.3.2.3. Others (IT and Record Management)
  • 13.4. Market Value Forecast, by Indication, 2020-2034
    • 13.4.1. Lifestyle Diseases
    • 13.4.2. Cancer and Autoimmune Diseases
    • 13.4.3. Infectious Diseases
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.5.1. Hospitals
    • 13.5.2. Clinics
    • 13.5.3. Retail Pharmacies
    • 13.5.4. E-commerce
    • 13.5.5. Drugs Stores
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. GCC Countries
    • 13.6.2. South Africa
    • 13.6.3. Rest of Middle East & Africa
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Product Type
    • 13.7.2. By Indication
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. Abbott Laboratories
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Type Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Koninklijke Philips N.V.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Type Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. F. Hoffmann-La Roche Ltd.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Type Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Merck & Co., Inc.
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Type Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Novartis AG
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Type Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Johnson & Johnson
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Type Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Teva Pharmaceutical Industries Ltd.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Type Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. AstraZeneca
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Type Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GlaxoSmithKline plc
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Type Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Lupin
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Type Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Tata Consultancy Services Ltd.
      • 14.3.11.1. Company Overview
      • 14.3.11.2. Product Type Portfolio
      • 14.3.11.3. SWOT Analysis
      • 14.3.11.4. Financial Overview
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Sun Pharmaceutical Industries Ltd.
      • 14.3.12.1. Company Overview
      • 14.3.12.2. Product Type Portfolio
      • 14.3.12.3. SWOT Analysis
      • 14.3.12.4. Financial Overview
      • 14.3.12.5. Strategic Overview
    • 14.3.13. Huadong Medicine Co., Ltd.
      • 14.3.13.1. Company Overview
      • 14.3.13.2. Product Type Portfolio
      • 14.3.13.3. SWOT Analysis
      • 14.3.13.4. Financial Overview
      • 14.3.13.5. Strategic Overview